Skip to main content
main-content

The independent medical news service

04-06-2019 | Breast cancer | Video

ASCO 2019: Low-fat diet linked to reduced risk of breast cancer mortality

Rowan Chlebowski discusses the latest update from the Women’s Health Initiative Dietary Modification clinical trial showing the positive impact of a healthy diet on the risk of breast cancer death in postmenopausal women. He also touches upon how the metabolic syndrome may modify this risk (5:52).

02-06-2019 | Breast cancer | Video

ASCO 2019: Ribociclib addition boosts OS in premenopausal advanced breast cancer patients

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

02-05-2019 | Oncology | News | Article

Biologic, genetic markers predict radiation toxicity in oncology patients

A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.

23-04-2019 | Oncology | News | Article

SABR may improve survival in oligometastatic cancer

The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.

01-04-2019 | Oncology | News | Article

Mesothelin-targeted CAR T-cell therapy shows promise for malignant pleural disease

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

07-02-2019 | Breast cancer | News | Article

Celecoxib may be contraindicated for some breast cancer patients

Use of the cyclooxygenase 2 inhibitor celecoxib during neoadjuvant taxane-based chemotherapy is associated with adverse survival outcomes in certain subgroups of patients with breast cancer, shows a post-hoc analysis of the REMAGUS02 trial.

Image Credits